Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...

Hims & Hers hit the bullseye with its Super Bowl ad, sparking a surge in clicks to its site.The ad also hit a nerve with the ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform consumers.

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Popular GLP-1 medications approved for weight loss ... people with diabetes who were treated by the Veterans Health Administration for an average of almost four years between October 2017 and ...

Within this web, GLP-1 use was associated with a lower risk of cardiovascular, kidney and liver issues. While Ozempic is currently approved by the Food and Drug Administration to treat Type 2 ...

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...